We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Sandoz Says High Court Should Review BPCIA To Avoid Delay For Patient Access To Biosimilar

Mealey's (July 15, 2016, 10:01 AM EDT) -- WASHINGTON, D.C. — Sandoz Inc. argues in a brief filed May 31 that the U.S. Supreme Court should consider reviewing the Biologics Price Competition and Innovation Act (BPCIA) because until it...
To view the full article, register now.